TY - JOUR
T1 - HER-2/neu expression in prostate adenocarcinoma
T2 - A systematic review and meta-analysis
AU - Neto, Ary Serpa
AU - Tobias-Machado, Marcos
AU - Wroclawski, Marcelo Langer
AU - Fonseca, Fernando Luiz Affonso
AU - Teixeira, Gabriel Kushiyama
AU - Amarante, Rodrigo Dal Moro
AU - Wroclawski, Eric Roger
AU - Del Giglio, Auro
PY - 2010/9
Y1 - 2010/9
N2 - Purpose: HER-2/neu has been linked to the clinical progression of hormone independent prostate cancer. We performed a meta-analysis to investigate the prognostic impact of HER-2/neu over expression in patients with prostate adenocarcinoma, and its correlation with other pathological and clinical variables. Materials and Methods: We searched the MEDLINE®, Embase®, CancerLit® and ASCO® abstract databases for published studies of HER-2/neu protein expression in primary prostate cancer tissue with a median followup of greater than 2 years and data on survival in patients with and without HER-2/neu over expression. We separately analyzed studies reporting HER-2/neu soluble receptor levels in patients with prostate cancer. Results: We included 38 articles with a total of 5,976 patients. The overall RR of death in those with HER-2/neu over expression in the primary tumor was 1.63 (95% CI 1.471.82, p <0.0001). In the presence of over expression the recurrence RR was 1.87 (95% CI 1.592.21, p <0.0001). High HER-2/neu extracellular domain levels also correlated with death (RR 2.01, 95% CI 1.213.35, p = 0.007) and recurrence (RR 1.74, 95% CI 1.412.15, p <0.0001). Conclusions: There is a consistent association of HER-2/neu over expression and Gleason less than 7 with a higher RR of death and recurrence in patients with prostate cancer. Further clinical trials should test the hypothesis that HER-2/neu is a marker of a clinically worse outcome in patients with prostate cancer and a potential target for therapy.
AB - Purpose: HER-2/neu has been linked to the clinical progression of hormone independent prostate cancer. We performed a meta-analysis to investigate the prognostic impact of HER-2/neu over expression in patients with prostate adenocarcinoma, and its correlation with other pathological and clinical variables. Materials and Methods: We searched the MEDLINE®, Embase®, CancerLit® and ASCO® abstract databases for published studies of HER-2/neu protein expression in primary prostate cancer tissue with a median followup of greater than 2 years and data on survival in patients with and without HER-2/neu over expression. We separately analyzed studies reporting HER-2/neu soluble receptor levels in patients with prostate cancer. Results: We included 38 articles with a total of 5,976 patients. The overall RR of death in those with HER-2/neu over expression in the primary tumor was 1.63 (95% CI 1.471.82, p <0.0001). In the presence of over expression the recurrence RR was 1.87 (95% CI 1.592.21, p <0.0001). High HER-2/neu extracellular domain levels also correlated with death (RR 2.01, 95% CI 1.213.35, p = 0.007) and recurrence (RR 1.74, 95% CI 1.412.15, p <0.0001). Conclusions: There is a consistent association of HER-2/neu over expression and Gleason less than 7 with a higher RR of death and recurrence in patients with prostate cancer. Further clinical trials should test the hypothesis that HER-2/neu is a marker of a clinically worse outcome in patients with prostate cancer and a potential target for therapy.
KW - adenocarcinoma
KW - genes, erbB-2
KW - mortality
KW - neoplasm recurrence, local
KW - prostate
UR - http://www.scopus.com/inward/record.url?scp=77956629278&partnerID=8YFLogxK
U2 - 10.1016/j.juro.2010.04.077
DO - 10.1016/j.juro.2010.04.077
M3 - Review Article
C2 - 20663525
AN - SCOPUS:77956629278
VL - 184
SP - 842
EP - 850
JO - Journal of Urology
JF - Journal of Urology
SN - 0022-5347
IS - 3
ER -